Novo Nordisk is changing its name and its culture to try to compete in the GLP-1 diet-drug wars
The Danish drug giant behind Ozempic is competing with Eli Lilly in the market for weight-loss drugs.
AI brief
Pulse reads the full article- What happened
- Why it matters
- What to watch
Sign in to get the AI brief. Pulse explains what happened, why it matters, what to watch and who's exposed. Free for members.
Sign in to read the brief
